Morgan Stanley, Leerink, Stifel and Cantor Fitzgerald acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential
- Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC
- Closing Bell Movers: Credo Technology jumps 11% on earnings
- Trevi Therapeutics Terminates ATM Prospectus with Leerink
- Trevi Therapeutics price target raised to $23 from $20 at Oppenheimer